Eisai launches Zebinix in the UK
This article was originally published in Scrip
Executive Summary
Eisai Pharmaceuticals has launched its Zebinix (eslicarbazepine acetate) in the UK as an adjunctive treatment for epilepsy in adults with partial-onset seizures, with or without secondary generalisation. The drug – which is already available in Denmark, Germany and Austria – will cost £5.14 per once-daily 800mg tablet in the UK.